Acquisition Details

Marksans Pharma Limited has entered into a definitive agreement to acquire 100% of the share capital of Netherlands-based QliniQ B.V. The total consideration for the acquisition is €7,500,000 (approximately ₹79.1 crore based on conversion rate implied in disclosure). The acquisition will be completed through cash consideration.

Target Company Profile

QliniQ B.V. is a Netherlands-based pharmaceutical and medical products company engaged in distribution and commercialization of niche prescription medicines and medical devices. The company is headquartered in Oldenzaal, Netherlands and operates across wholesaler, pharmacy, hospital, and insurance-led tender channels. It maintains EU GDP-licensed wholesale and warehousing capability and operates a direct-to-customer webshop.

Financial Performance of QliniQ

For the financial year ended December 31, 2025:

  • Net turnover: €9,346,227 (approximately ₹985 million)
  • Profit before tax: €1,337,388
  • Net profit: €1,007,652 (approximately ₹106 million)
  • Equity (net worth): €1,452,862 as of December 31, 2025

The company has delivered strong growth with revenue increasing at a CAGR of approximately 41% between FY2023 and FY2025. QliniQ maintains a debt-free balance sheet.

Strategic Rationale

The acquisition will enable Marksans to utilize QliniQ's front-end sales and marketing infrastructure for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans' presence in European markets through:

  • Established sales, marketing and distribution capabilities in the Netherlands
  • Access to long-standing relationships with leading wholesalers, pharmacies, hospitals and health insurers
  • Participation in insurer-led tender channels with established relationships with leading Dutch health insurers
  • EU GDP-compliant warehousing, wholesale distribution and regulatory infrastructure
  • Multiple routes to market through wholesalers, pharmacies and direct-to-consumer channels

Transaction Structure

The acquisition involves 100% shareholding of QliniQ B.V. The transaction is not a related party transaction, and the promoter/promoter group of Marksans has no interest in QliniQ B.V.

Regulatory Approvals and Timeline

No governmental or regulatory approvals are required for the acquisition. The transaction is expected to be completed by June 15, 2026, or any other date as the parties agree in writing.

Business Impact

The acquisition provides Marksans with direct market access capabilities in the Netherlands and enhances its ability to commercialize existing and future products across regulated European markets. QliniQ's portfolio spans women's health (contraceptives and menopause), dermatology, respiratory/ENT, endocrinology and gastroenterology, with several first-to-market positions.

Company Background

Marksans Pharma Limited (BSE: 524404 | NSE: MARKSANS) reported consolidated total income of approximately ₹3,033 crore and profit after tax of approximately ₹420 crore for the financial year ended March 31, 2026.